Answers are grounded in this paper and cite their sources.
Inebilizumab reduced the risk of flares of IgG4-related disease and increased the likelihood of flare-free complete remission at 1 year, confirming the role of CD19-targeted B-cell depletion as a potential treatment for IgG4-related disease. (Funded by Amgen; MITIGATE ClinicalTrials.gov number, NCT04540497.).
No takes yet. Share an insight, caveat, or question.
Stone et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: